News
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Dallas News
August 30, 2011
CoLucid Pharmaceuticals Receives Clearance For Investigational New Drug (IND) Application For Lasmiditan For The Treatment Of Acute Migraine
Medical News Today
August 20, 2011
CoLucid in talks with partners for novel migraine treatment
MedCity News
August 18, 2011
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan in the treatment of acute migraine attacks
Download the PDF
June 9, 2010
CoLucid Pharmaceuticals
Indianapolis, IN
CoLucid Pharmaceuticals is a clinical stage biopharmaceutical company developing therapeutics to treat neurological dysfunctions. CoLucid’s lead program is based on a potent and selective 5-HT1F receptor agonist that has the potential to be useful in the acute treatment and/or prevention or prophylaxis of migraine headaches. The company also possesses a robust chemistry platform that will produce unique bifunctional neuromodulators to treat indications such as Alzheimer's disease.